Herbalife price target raised to $17 from $13 at Mizuho

Mizuho analyst John Baumgartner raised the firm’s price target on Herbalife to $17 from $13 and keeps a Neutral rating on the shares following the “solid” Q2 report. However, macro headwinds likely limit second half of 2023 revenue upside and unlocking larger distributor productivity is a work-in-progress with uncertain timing, the analyst tells investors in a research note.